Best Stocks: Three healthcare names to ponder including a biotech back to levels not seen in a decade
CNBC: Investing
JUNE 9, 2025
This dual-indication approval not only boosts Alnylam's revenue potential but also strengthens its path toward profitability, making AMVUTTRA a key growth driver for the company and a pivotal reason for recent momentum. Josh — Allow for short-term consolidation in the $300 area, await the next catalyst.
Let's personalize your content